Vaccine production in Bandung, Indonesia (archive; not the Ervebo allocation described in this report).
Vaccine production in Bandung, Indonesia (archive; not the Ervebo allocation described in this report). Illustrative archive image; not a photograph of the reported 2026 event. Image: Ümit Kartoğlu for VOA / Wikimedia Commons, Public domain. Resized and converted to JPEG; thumbnails may be cropped by the page layout.

WHO and Africa CDC welcomed an initial allocation of 70,000 Ervebo vaccine doses to the Democratic Republic of the Congo on 20 August. The release from the global stockpile followed a government request for help responding to the Bundibugyo virus outbreak.

Of the allocation, 20,000 doses were intended for a Phase 3 trial and 50,000 for frontline and health workers under current expert recommendations. Ervebo is licensed against Ebola virus disease associated with the previously named Zaire ebolavirus; protection against Bundibugyo virus in humans had not been established. The clinical trial therefore serves an evidence-generating role. WHO stressed informed consent and clear communication about possible benefits, risks and limitations, alongside a response led with affected communities.